This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (38)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Review  • Thrombolysis  • Venous Thromboembolism  • Alert me on articles by topic

Past, Present, and Future

Thomas M. Hyers, MD

Arch Intern Med. 2003;163:759-768.

Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, represents a significant source of morbidity and mortality in the United States and worldwide. The pharmacologic management of venous thromboembolic disease has witnessed significant advances since oral anticoagulant and heparin therapies began to gain widespread use more than 50 years ago. Cumulative clinical experience gained from using these 2 classes of antithrombotic agents for the prevention and treatment of venous thromboembolism in high-risk patients pointed to a number of efficacy and safety limitations. This prompted further research and the eventual introduction, in the 1980s, of low-molecular-weight heparin(s) as a potentially superior therapeutic modality. Within the last decade the pace of development of newer classes of antithrombotic agents for venous thromboembolism prevention and treatment (as well as other indications) has accelerated. Among agents at late stages of investigation are ximelagatran (a direct thrombin inhibitor), nematode anticoagulant peptide c2 (a tissue factor VIIa inhibitor), and sodium N-[8(2-hydroxylbenzoyl)amino]caprylate (SNAC)/heparin (a heparin derivative). The most recently approved agents for venous thromboembolism indications include the heparinoid, danaparoid sodium, and the newly introduced selective factor Xa inhibitor, fondaparinux.

From the Department of Internal Medicine, St Louis University School of Medicine, Care Clinical Research, St Louis, Mo. Dr Hyers is a paid consultant for Pharmacia, Aventis, Pharmion, AstraZeneca, Synergy, and Organon-Sanofi.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery
Troconiz et al.
J Clin Pharmacol 2007;47:371-382.
ABSTRACT | FULL TEXT  

Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach
Nutescu et al.
The Annals of Pharmacotherapy 2006;40:1558-1570.
ABSTRACT | FULL TEXT  

Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
Stangier et al.
J Clin Pharmacol 2005;45:555-563.
ABSTRACT | FULL TEXT  

Use of a Modified Dosing Weight for Heparin Therapy in a Morbidly Obese Patient
Schwiesow et al.
The Annals of Pharmacotherapy 2005;39:753-756.
ABSTRACT | FULL TEXT  

Impact of Prescribing Guidelines for Inpatient Anticoagulation
Schumock et al.
The Annals of Pharmacotherapy 2004;38:1570-1575.
ABSTRACT | FULL TEXT